𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Determining Factors in Innovation of Small Firm Networks: A case of Cross Industry Groups in Japan

✍ Scribed by Nobuya Fukugawa

Publisher
Springer US
Year
2006
Tongue
English
Weight
268 KB
Volume
27
Category
Article
ISSN
0921-898X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The role of firm resources and organizat
The role of firm resources and organizational attributes in determining entry timing: a cross-industry study
✍ Timothy S. Schoenecker; Arnold C. Cooper πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 2 views

We investigate the factors that influence the timing of entry of firms into new industries based on new technology. Consistent with previous research, it is hypothesized that firm resources and organizational attributes influence entry timing. Unlike previous research, there is specific consideratio

Transaction costs and capabilities as de
Transaction costs and capabilities as determinants of the R&D boundaries of the firm: a case study of the ten largest pharmaceutical firms in Japan
✍ Hiroyuki Odagiri πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 196 KB

## Abstract The boundaries of the firm are an important issue in relation not just with the make‐or‐buy decision in production but also with research and development (R&D). Firms depend on universities to gain scientific knowledge, outsource some of their R&D works, purchase patented technologies,

Dose escalation study of carboplatin wit
Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan
✍ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400